231 related articles for article (PubMed ID: 21151387)
1. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
3. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Azzarello J; Fung KM; Lin HK
J Histochem Cytochem; 2008 Sep; 56(9):853-61. PubMed ID: 18574251
[TBL] [Abstract][Full Text] [Related]
5. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Zakharov V; Lin HK; Azzarello J; McMeekin S; Moore KN; Penning TM; Fung KM
Int J Clin Exp Pathol; 2010 Jul; 3(6):608-17. PubMed ID: 20661409
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
7. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
8. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
9. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
[TBL] [Abstract][Full Text] [Related]
11. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC; Jin Y; Penning TM
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
[TBL] [Abstract][Full Text] [Related]
14. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
15. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
18. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
19. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
